BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10. [PMID: 16331092 DOI: 10.1097/01.hjh.0000194119.42722.21] [Cited by in Crossref: 206] [Cited by in F6Publishing: 126] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
2 Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev 2020;16:12-8. [PMID: 30987573 DOI: 10.2174/1573402115666190415161813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 Li Z, Li Y, Liu Y, Xu W, Wang Q. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis. J Clin Hypertens (Greenwich) 2017;19:1348-56. [PMID: 29067768 DOI: 10.1111/jch.13108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Schäfer HH, de Villiers JD, Sudano I, Theus GR, Sivukhina E, Burnier M, Dieterle T, Noll G. Management of hypertension in patients with diabetes mellitus and metabolic syndrome in Swiss primary care. Int J Clin Pract 2012;66:1125-6. [PMID: 23067037 DOI: 10.1111/ijcp.12000] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bilo G, Koch W, Hoshide S, Parati G. Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone. Hypertens Res 2014;37:836-44. [PMID: 24942766 DOI: 10.1038/hr.2014.26] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
6 Mukete BN, Cassidy M, Ferdinand KC, Le Jemtel TH. Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis. Am J Cardiovasc Drugs 2015;15:243-57. [PMID: 26055616 DOI: 10.1007/s40256-015-0129-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
7 Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension–European Society of Cardiology guidelines: specific indications rather than ranking for general usage. Journal of Hypertension 2008;26:164-8. [DOI: 10.1097/hjh.0b013e3282f52fa8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
8 Segura J, Banegas JR, García-donaire JA, Rodríguez-artalejo F, Cruz JJ, Praga M, Ruilope LM. Should Hypertension Guidelines Be Changed for Hypertensive Patients With the Metabolic Syndrome? J Clin Hypertension 2007;9:595-600. [DOI: 10.1111/j.1524-6175.2007.06522.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Chowdhury EK, Owen A, Ademi Z, Krum H, Johnston CI, Wing LM, Nelson MR, Reid CM; Second Australian National Blood Pressure Study Management Committee. Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study. Am J Hypertens 2014;27:199-206. [PMID: 24249722 DOI: 10.1093/ajh/hpt212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract 2008;62:781-90. [PMID: 18355239 DOI: 10.1111/j.1742-1241.2008.01713.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Berra C, Manfrini R, Regazzoli D, Radaelli MG, Disoteo O, Sommese C, Fiorina P, Ambrosio G, Folli F. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res 2020;160:105052. [PMID: 32650058 DOI: 10.1016/j.phrs.2020.105052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lleva RR, Inzucchi SE. Glucose, blood pressure, and cardiovascular risk. Circ Cardiovasc Qual Outcomes 2012;5:145-7. [PMID: 22438461 DOI: 10.1161/CIRCOUTCOMES.112.965046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Rydén L, Waeber B, Ruilope LM, Mancia G, Volpe M, Holzgreve H, Mogensen CE, Laurent S. The management of the type 2 diabetic patient with hypertension – too late and too little: Suggested improvements. Blood Pressure 2009;17:250-9. [DOI: 10.1080/08037050802513387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Zhou MS, Schulman IH, Raij L. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol 2009;296:H833-9. [PMID: 19151253 DOI: 10.1152/ajpheart.01096.2008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
15 Miao CY, Ye XF, Zhang W, Ji LN, Wang JG; ATTEND investigators. Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study. J Clin Hypertens (Greenwich) 2021;23:1399-404. [PMID: 34092020 DOI: 10.1111/jch.14264] [Reference Citation Analysis]
16 Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl 2007;2:25-30. [PMID: 18046976 DOI: 10.1080/08038020701561745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
17 Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Mancia G. Metabolic syndrome and cardiometabolic risk: an update. Blood Press 2009;18:7-16. [PMID: 19148840 DOI: 10.1080/08037050802677695] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
18 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. Journal of Hypertension 2006;24:2131-41. [DOI: 10.1097/01.hjh.0000249685.58370.28] [Cited by in Crossref: 100] [Cited by in F6Publishing: 67] [Article Influence: 6.7] [Reference Citation Analysis]
19 Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, Corsello SM, Pivonello R; ABC Study Group. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015;33:44-60. [PMID: 25415766 DOI: 10.1097/HJH.0000000000000415] [Cited by in Crossref: 75] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
20 Cavalieri L, Cremonesi G. Metabolic Effects of Manidipine. Am J Cardiovasc Drugs 2009;9:163-76. [DOI: 10.1007/bf03256573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosion E, Fagard R, Lindholm LH, Manolis A, Nilsson PM, Redon J, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL; Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad Europea., Sociedad Europea de Cardiología. [ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol 2007;60:968.e1-94. [PMID: 17915153 DOI: 10.1157/13109650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
22 Peyriere H, Eiden C, Macia J, Reynes J. Antihypertensive Drugs in Patients Treated with Antiretroviral. Ann Pharmacother 2012;46:703-9. [DOI: 10.1345/aph.1q546] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
23 Lobos JM, Ángel Royo-bordonada M, Brotons C, Álvarez-sala L, Armario P, Maiques A, Mauricio D, Sans S, Villar F, Lizcano Á, Gil-núñez A, de Álvaro F, Conthe P, Luengo E, del Río A, Cortés O, de Santiago A, Vargas MA, Martínez M, Lizarbe V. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Clínica e Investigación en Arteriosclerosis 2009;21:124-50. [DOI: 10.1016/s0214-9168(09)71131-3] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016;4:136-47. [PMID: 26489809 DOI: 10.1016/S2213-8587(15)00377-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 19] [Article Influence: 11.2] [Reference Citation Analysis]
25 Opie LH. Beta-blockade should not be among several choices for initial therapy of hypertension. Journal of Hypertension 2008;26:161-3. [DOI: 10.1097/hjh.0b013e3282f300a7] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
26 Beitelshees AL, Finck BN, Leone TC, Cresci S, Wu J, Province MA, Fabbrini E, Kirk E, Zineh I, Klein S, Spertus JA, Kelly DP. Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics 2010;20:231-8. [PMID: 20145583 DOI: 10.1097/FPC.0b013e3283377abc] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Nilsson PM, Hedblad B, Donaldson J, Berglund G. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press. 2007;16:95-100. [PMID: 17612907 DOI: 10.1080/08037050701396652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
28 Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens 2011;24:582-90. [PMID: 21331058 DOI: 10.1038/ajh.2011.8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
29 Volpe M, Tocci G, de la Sierra A, Kreutz R, Laurent S, Manolis AJ, Tsioufis K. Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Press Cardiovasc Prev 2017;24:463-72. [PMID: 29086364 DOI: 10.1007/s40292-017-0239-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
30 Scheen AJ. Type 2 Diabetes and Thiazide Diuretics. Curr Diab Rep 2018;18:6. [PMID: 29399724 DOI: 10.1007/s11892-018-0976-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
31 Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G; Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008;26:1891-1900. [PMID: 18806611 DOI: 10.1097/hjh.0b013e328302ca38] [Cited by in Crossref: 82] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
32 Kjeldsen SE, Mcinnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimský J, Zanchetti A, For The Value Trial Investigators. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure 2009;17:170-7. [DOI: 10.1080/08037050802169644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
33 Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019;42:1235-481. [PMID: 31375757 DOI: 10.1038/s41440-019-0284-9] [Cited by in Crossref: 322] [Cited by in F6Publishing: 196] [Article Influence: 322.0] [Reference Citation Analysis]
34 Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy 2014;5:767-76. [DOI: 10.1586/14779072.5.4.767] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
35 Sesti G, Volpe M, Cosentino F, Crepaldi G, Del Prato S, Mancia G, Manzato E, Menotti A, Tiengo A, Zaninelli A. Metabolic Syndrome: Diagnosis and Clinical Management, an Official Document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC)??? Guest Editor: E. Agabiti Rosei, President of the Italian Society of Hypertension. High Blood Pressure & Cardiovascular Prevention 2006;13:185-98. [DOI: 10.2165/00151642-200613040-00007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Lobos J, Royo-bordonada M, Brotons C, Álvarez-sala L, Armario P, Maiques A, Mauricio D, Sans S, Villar F, Lizcano Á, Gil-núñez A, de Álvaro F, Conthe P, Luengo E, del Río A, Cortés O, de Santiago A, Varga M, Martínez M, Lizarbe V. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Revista Clínica Española 2009;209:279-302. [DOI: 10.1016/s0014-2565(09)71477-8] [Cited by in Crossref: 15] [Article Influence: 1.3] [Reference Citation Analysis]
37 Chen J, Chou C, Lee YL, Tsai W, Lin C, Huang Y, Chen J. Association of Central Aortic Pressures Indexes With Development of Diabetes Mellitus in Essential Hypertension. American Journal of Hypertension 2010;23:1069-73. [DOI: 10.1038/ajh.2010.145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
38 . 2007 ESH‐ESC Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressure 2009;16:135-232. [DOI: 10.1080/08037050701461084] [Cited by in Crossref: 209] [Cited by in F6Publishing: 167] [Article Influence: 17.4] [Reference Citation Analysis]
39 Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, Bakris GL, Giles TD. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16:72-79. [PMID: 17612904 DOI: 10.1080/08037050701338985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
40 Padilla MCA, Armas-hernández MJ, Hernández RH, Israili ZH, Valasco M. Update of Diuretics in the Treatment of Hypertension. American Journal of Therapeutics 2007;14:154-60. [DOI: 10.1097/01.pap.0000249938.05382.d0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
41 Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence 2012;6:449-55. [PMID: 22791982 DOI: 10.2147/PPA.S23232] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
42 Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 2009;5:361-8. [PMID: 19475773 DOI: 10.2147/vhrm.s4331] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
43 Tabatabaei-malazy O, Nikfar S, Larijani B, Abdollahi M. Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities. Expert Opinion on Pharmacotherapy 2016;17:2449-60. [DOI: 10.1080/14656566.2016.1258057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
44 Al Khaja KA, Sequeira RP, Damanhori AH. Medication prescribing errors pertaining to cardiovascular/antidiabetic medications: a prescription audit in primary care: Prescribing errors in primary care. Fundamental & Clinical Pharmacology 2012;26:410-7. [DOI: 10.1111/j.1472-8206.2011.00924.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
45 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018;36:1953-2041. [PMID: 30234752 DOI: 10.1097/HJH.0000000000001940] [Cited by in Crossref: 1002] [Cited by in F6Publishing: 227] [Article Influence: 334.0] [Reference Citation Analysis]
46 Weng CM, Chou CH, Huang YY, Lin CC, Liu YW, Tsai WC. Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients. Heart Vessels 2010;25:386-91. [PMID: 20676960 DOI: 10.1007/s00380-009-1218-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
47 Du HW, Li JY, He Y. Glycemic and blood pressure control in older patients with hypertension and diabetes: association with carotid atherosclerosis. J Geriatr Cardiol 2011;8:24-30. [PMID: 22783281 DOI: 10.3724/SP.J.1263.2011.00024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Shlomai G, Kopel E, Goldenberg I, Grossman E. Temporal trends in management of hypertension among Israeli adults, 2002-2010: lesson from the Acute Coronary Syndromes Israeli Survey (ACSIS). J Am Soc Hypertens 2014;8:94-102. [PMID: 24269166 DOI: 10.1016/j.jash.2013.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Mancia G, Rea F, Cuspidi C, Grassi G, Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. Journal of Hypertension 2017;35:225-33. [DOI: 10.1097/hjh.0000000000001181] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 7.8] [Reference Citation Analysis]
50 Redon J, Cífková R. The metabolic syndrome in hypertension: diagnostic and therapeutic implications. Curr Hypertens Rep 2007;9:305-13. [PMID: 17686382 DOI: 10.1007/s11906-007-0056-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
51 Mancia G. Preventing new-onset diabetes in thiazide-treated patients. The Lancet Diabetes & Endocrinology 2016;4:90-2. [DOI: 10.1016/s2213-8587(15)00391-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
52 Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162. [PMID: 24711954 DOI: 10.1155/2014/943162] [Cited by in Crossref: 847] [Cited by in F6Publishing: 708] [Article Influence: 121.0] [Reference Citation Analysis]
53 Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. [PMID: 23771844 DOI: 10.1093/eurheartj/eht151] [Cited by in Crossref: 2928] [Cited by in F6Publishing: 1867] [Article Influence: 366.0] [Reference Citation Analysis]
54 Reynolds K, Wildman RP. Update on the metabolic syndrome: Hypertension. Current Science Inc 2009;11:150-5. [DOI: 10.1007/s11906-009-0026-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
55 Graham I. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:1-45. [DOI: 10.1016/j.atherosclerosis.2007.08.024] [Cited by in Crossref: 153] [Cited by in F6Publishing: 109] [Article Influence: 10.9] [Reference Citation Analysis]
56 Waeber B, Feihl F, Ruilope LM. Fixed-Dose Combinations as Initial Therapy for Hypertension: A Review of Approved Agents and a Guide to Patient Selection. Drugs 2009;69:1761-76. [DOI: 10.2165/11316710-000000000-00000] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
57 Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18:308-347. [PMID: 20001654 DOI: 10.3109/08037050903450468] [Cited by in Crossref: 169] [Cited by in F6Publishing: 109] [Article Influence: 15.4] [Reference Citation Analysis]
58 Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology. Medical Hypotheses 2009;73:770-80. [DOI: 10.1016/j.mehy.2008.10.039] [Cited by in Crossref: 143] [Cited by in F6Publishing: 101] [Article Influence: 11.9] [Reference Citation Analysis]
59 Gorostidi M, de la Sierra A. Combination therapy in hypertension. Adv Ther 2013;30:320-36. [PMID: 23553510 DOI: 10.1007/s12325-013-0020-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
60 Gallagher M, Perkovic V, Chalmers J. Diuretics: A modern day treatment option? (Review Article). Nephrology 2006;11:419-27. [DOI: 10.1111/j.1440-1797.2006.00598.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
61 Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. [PMID: 23817082 DOI: 10.1097/01.hjh.0000431740.32696.cc] [Cited by in Crossref: 3203] [Cited by in F6Publishing: 1982] [Article Influence: 457.6] [Reference Citation Analysis]
62 Francischetti EA, Celoria BM, Francischetti A, Genelhu VA. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther 2008;6:289-303. [PMID: 18327991 DOI: 10.1586/14779072.6.3.289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
63 García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, Soler MJ. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. Front Med (Lausanne) 2021;8:655871. [PMID: 33928108 DOI: 10.3389/fmed.2021.655871] [Reference Citation Analysis]
64 Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, De Ciuceis C, Porteri E, Boari GE, Rezzani R, Speca S, Favero G, Martinotti S, Toniato E, Platto C, Agabiti-rosei E. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. Journal of Hypertension 2008;26:1595-601. [DOI: 10.1097/hjh.0b013e328304b060] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
65 Yang Y, Xu H. Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. J Cell Mol Med 2017;21:1742-50. [PMID: 28230330 DOI: 10.1111/jcmm.13096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
66 Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro and microvascular events. Journal of Hypertension 2007;25:S7-S12. [DOI: 10.1097/01.hjh.0000271503.85196.9a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
67 Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol 2010;5:75-100. [PMID: 20305727 DOI: 10.2217/ijr.09.73] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
68 Zhang W, Liu CY, Ji LN, Wang JG; ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens (Greenwich) 2020;22:212-20. [PMID: 31944560 DOI: 10.1111/jch.13793] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
69 Brown MJ, Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I. Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. BMJ Open 2015;5:e008086. [PMID: 26253567 DOI: 10.1136/bmjopen-2015-008086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
70 Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol 2011;31:542-52. [PMID: 22099511 DOI: 10.1016/j.semnephrol.2011.09.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
71 Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, Sowers JR. Reversal of Diuretic-Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. J CardioMetab Syndrome 2008;3:18-25. [DOI: 10.1111/j.1559-4572.2008.07819.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
72 Mogensen C. Microalbuminuria, renal disease, metabolic syndrome and risks in diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2007;1:127-33. [DOI: 10.1016/j.dsx.2006.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 de Araújo MFM, dos Santos Alves PDJ, Veras VS, de Araújo TM, Zanetti ML, Damasceno MMC. Drug interactions in Brazilian type 2 diabetes patients: Drugs interactions. Int J Nurs Pract 2013;19:423-30. [DOI: 10.1111/ijn.12078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 López-Jaramillo P, Pradilla LP, Lahera V, Sieger FA, Rueda-Clausen CF, Márquez GA. A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA". Trials 2006;7:28. [PMID: 16959033 DOI: 10.1186/1745-6215-7-28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Susic D, Varagic J. Obesity: A Perspective from Hypertension. Med Clin North Am 2017;101:139-57. [PMID: 27884225 DOI: 10.1016/j.mcna.2016.08.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
76 Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:E1-40. [PMID: 17726406 DOI: 10.1097/01.hjr.0000277984.31558.c4] [Cited by in Crossref: 233] [Cited by in F6Publishing: 209] [Article Influence: 16.6] [Reference Citation Analysis]
77 Ferguson MA, Flynn JT. Rational use of antihypertensive medications in children. Pediatr Nephrol. 2014;29:979-988. [PMID: 23715784 DOI: 10.1007/s00467-013-2510-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
78 Warmack TS, Estes MA, Heldenbrand S, Franks AM. β-Adrenergic Antagonists in Hypertension: A Review of the Evidence. Ann Pharmacother 2009;43:2031-43. [DOI: 10.1345/aph.1m381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
79 Basile JN. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract 2009;63:656-66. [PMID: 19220522 DOI: 10.1111/j.1742-1241.2009.02009.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
80 Palmer BF. Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am J Cardiovasc Drugs 2008;8:9-14. [PMID: 18303933 DOI: 10.2165/00129784-200808010-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
81 Bakris GL, Sowers JR; American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) 2008;10:707-13; discussion 714-5. [PMID: 18844766 DOI: 10.1111/j.1751-7176.2008.00012.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
82 Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract. 2007;76 Suppl 1:S13-S21. [PMID: 17320999 DOI: 10.1016/j.diabres.2007.01.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
83 Goldstein JA, Bastarache LA, Denny JC, Roden DM, Pulley JM, Aronoff DM. Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale genomic and electronic health records data to repurpose medications. Pharmacol Res 2018;130:44-51. [PMID: 29448118 DOI: 10.1016/j.phrs.2018.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
84 Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386-393. [PMID: 20442753 DOI: 10.1038/hr.2010.9] [Cited by in Crossref: 308] [Cited by in F6Publishing: 227] [Article Influence: 28.0] [Reference Citation Analysis]
85 Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010;11:2599-607. [PMID: 20426702 DOI: 10.1517/14656566.2010.482561] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
86 Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Therapy 2010;27:426-43. [DOI: 10.1007/s12325-010-0039-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
87 Jong G, Chang M, Tien L, Li S, Liou Y, Lung C, Ma T. Antihypertensive Drugs and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study. Cardiovascular Therapeutics 2009;27:159-63. [DOI: 10.1111/j.1755-5922.2009.00092.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Hamer M, Chida Y. Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis. J Hypertens. 2007;25:2361-2369. [PMID: 17984654 DOI: 10.1097/hjh.0b013e3282efc214] [Cited by in Crossref: 157] [Cited by in F6Publishing: 53] [Article Influence: 12.1] [Reference Citation Analysis]
89 Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA. Treatment of hypertension in patients with diabetes--an update. J Am Soc Hypertens 2010;4:62-7. [PMID: 20400050 DOI: 10.1016/j.jash.2010.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
90 Mancia G, Grassi G. Individualization of antihypertensive drug treatment. Diabetes Care 2013;36 Suppl 2:S301-6. [PMID: 23882063 DOI: 10.2337/dcS13-2013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
91 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. [PMID: 30165516 DOI: 10.1093/eurheartj/ehy339] [Cited by in Crossref: 2877] [Cited by in F6Publishing: 1596] [Article Influence: 959.0] [Reference Citation Analysis]
92 Perl S, Schmölzer I, Sourij H, Pressl H, Eder M, Zweiker R, Wascher TC. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. International Journal of Cardiology 2010;139:289-96. [DOI: 10.1016/j.ijcard.2008.10.048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
93 Matsuoka K, Saito M, Shibata K, Sekine M, Shitara H, Taya C, Zhang X, Takahashi TA, Kohno K, Kikkawa Y, Yonekawa H. Generation of mouse models for type 1 diabetes by selective depletion of pancreatic beta cells using toxin receptor-mediated cell knockout. Biochem Biophys Res Commun 2013;436:400-5. [PMID: 23747725 DOI: 10.1016/j.bbrc.2013.05.114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
94 Mancia G. Prevention of risk factors: beta-blockade and hypertension. European Heart Journal Supplements 2009;11:A3-8. [DOI: 10.1093/eurheartj/sup003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
95 Lonati C, Morganti A, Comarella L, Mancia G, Zanchetti A; IPERDIA Study Group. Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study. J Hypertens 2008;26:1801-8. [PMID: 18698215 DOI: 10.1097/HJH.0b013e328307a07f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
96 Richards TR, Tobe SW. Combining Other Antihypertensive Drugs With β-Blockers in Hypertension: A Focus on Safety and Tolerability. Canadian Journal of Cardiology 2014;30:S42-6. [DOI: 10.1016/j.cjca.2013.08.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
97 Otani L, Ninomiya T, Murakami M, Osajima K, Kato H, Murakami T. Sardine peptide with angiotensin I-converting enzyme inhibitory activity improves glucose tolerance in stroke-prone spontaneously hypertensive rats. Biosci Biotechnol Biochem 2009;73:2203-9. [PMID: 19809178 DOI: 10.1271/bbb.90311] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
98 Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens. 2007;25:2463-2470. [PMID: 17984668 DOI: 10.1097/hjh.0b013e3282f063d5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 4.1] [Reference Citation Analysis]
99 Palmer BF, Naderi ASA. Metabolic complications associated with use of thiazide diuretics. Journal of the American Society of Hypertension 2007;1:381-92. [DOI: 10.1016/j.jash.2007.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
100 Piecha G, Adamczak M, Chudek J, Wiecek A. Indapamide Decreases Plasma Adiponectin Concentration in Patients with Essential Hypertension. Kidney Blood Press Res 2007;30:187-94. [DOI: 10.1159/000103279] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
101 Panoulas VF, John H, Kitas GD. Six-step management of hypertension in patients with rheumatoid arthritis. Future Rheumatology 2008;3:21-35. [DOI: 10.2217/17460816.3.1.21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
102 Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wühl E, Zanchetti A. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016;34:1887-920. [PMID: 27467768 DOI: 10.1097/HJH.0000000000001039] [Cited by in Crossref: 469] [Cited by in F6Publishing: 96] [Article Influence: 117.3] [Reference Citation Analysis]
103 Mancia G, Grassi G. The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis 2008;2:5-12. [PMID: 19124403 DOI: 10.1177/1753944707087409] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
104 Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressure 2013;22:193-278. [DOI: 10.3109/08037051.2013.812549] [Cited by in Crossref: 271] [Cited by in F6Publishing: 127] [Article Influence: 33.9] [Reference Citation Analysis]
105 Segura J, Roldán C, García-Donaire JA, Ruilope LM. Prediabetes and cardiovascular risk in hypertensive patients. Curr Hypertens Rep 2006;8:97-100. [PMID: 16672140 DOI: 10.1007/s11906-006-0001-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Press. 2006;15:71-79. [PMID: 16754269 DOI: 10.1080/08037050600771583] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
107 . Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Revista Española de Cardiología 2008;61:82.e1-82.e49. [DOI: 10.1157/13114961] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
108 Weir MR, Hanes DS, Klassen DK. Antihypertensive Drugs. Brenner and Rector's The Kidney. Elsevier; 2012. pp. 1824-78. [DOI: 10.1016/b978-1-4160-6193-9.10049-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Mancia G, Grassi G. Impact of new clinical trials on recent guidelines on hypertension management. Ann Med 2011;43:124-32. [PMID: 21254905 DOI: 10.3109/07853890.2010.543922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
110 Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother 2017;8:155-65. [PMID: 29472747 DOI: 10.4103/jpp.JPP_34_17] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
111 Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: Myth versus reality. Current Science Inc 2006;8:403-8. [DOI: 10.1007/s11906-006-0086-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
112 Mancia G, Giannattasio C, Seravalle G, Quarti-trevano F, Grassi G. Protective effects of renin–angiotensin blockade beyond blood pressure control. J Hum Hypertens 2009;23:570-7. [DOI: 10.1038/jhh.2008.171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
113 Currie O, Mangin D, Williman J, McKinnon-Gee B, Bridgford P. The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study. BMJ Open 2013;3:e003475. [PMID: 24270832 DOI: 10.1136/bmjopen-2013-003475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
114 Rump LC, Sellin L. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opinion on Pharmacotherapy 2010;11:2231-42. [DOI: 10.1517/14656566.2010.510834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
115 Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens. 2008;26:1602-1611. [PMID: 18622239 DOI: 10.1097/hjh.0b013e328302f10d] [Cited by in Crossref: 47] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
116 Maruhashi T, Kihara Y, Higashi Y. Perspectives on the management of hypertension in Japan. Expert Opinion on Pharmacotherapy 2020;21:1179-87. [DOI: 10.1080/14656566.2020.1724958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909-920. [PMID: 17414649 DOI: 10.1097/hjh.0b013e328048d004] [Cited by in Crossref: 261] [Cited by in F6Publishing: 80] [Article Influence: 18.6] [Reference Citation Analysis]
118 Giles TD. Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence. J Clin Hypertens (Greenwich) 2009;11:512-9. [PMID: 19751467 DOI: 10.1111/j.1559-4572.2009.00064.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158. [PMID: 19838131 DOI: 10.1097/hjh.0b013e328333146d] [Cited by in Crossref: 1047] [Cited by in F6Publishing: 170] [Article Influence: 95.2] [Reference Citation Analysis]
120 Grassi G, Quarti-trevano F, Seravalle G, Dell'oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases 2007;17:473-81. [DOI: 10.1016/j.numecd.2007.01.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
121 Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes mellitus: . Current Opinion in Nephrology and Hypertension 2007;16:256-60. [DOI: 10.1097/mnh.0b013e328057dea2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
122 Banks J, Kumari M, Smith JP, Zaninotto P. What explains the American disadvantage in health compared with the English? The case of diabetes. J Epidemiol Community Health 2012;66:259-64. [PMID: 20889587 DOI: 10.1136/jech.2010.108415] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B, Boström KB, Manhem K. Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD). Journal of the American Society of Hypertension 2014;8:882-90. [DOI: 10.1016/j.jash.2014.08.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
124 Toh R, Ishida T, Nishimura K, Nonaka H, Inoue Y, Kitagawa Y, Suematsu M, Miki T, Emoto N, Hirata K. Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. Hypertens Res 2012;35:1080-6. [PMID: 22786569 DOI: 10.1038/hr.2012.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
125 Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, Kitas GD. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1286-98. [PMID: 18467370 DOI: 10.1093/rheumatology/ken159] [Cited by in Crossref: 168] [Cited by in F6Publishing: 144] [Article Influence: 12.9] [Reference Citation Analysis]
126 Meredith PA, Östergren J. Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies? J Renin Angiotensin Aldosterone Syst 2006;7:64-73. [DOI: 10.3317/jraas.2006.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]